trial

A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder

NCTId NCT01116830
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 29 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2014-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
29 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2010-11
Primary completion
2014-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
RO4917838Standard Antipsychotic Therapy

Sponsors

Hoffmann-La RocheLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
29
Phase
PHASE1
Primary Completion Date
2014-02
Status
COMPLETED
relationships
The graph out of here
drug
RO4917838
drug
Standard Antipsychotic Therapy
drug
lead_sponsor
Hoffmann-La Roche
company
indication
Schizophrenia
indication
Schizophrenia
indication